Physician profile
Pouya Mohajer
NPI 1871819599
$6,747.53
in general payments reported to CMS, 2019-2025
21 companies · $1,259 in 2025
The $1,259 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $536 · 2021: $1,068 · 2022: $2,382 · 2023: $399 · 2024: $757 · 2025: $1,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,415.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,941.59 | 2019-2025 | Intracept, General - Pain Management, General - Therapies |
| Shockwave Medical, INC | $1,015.77 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Penumbra, INC. | $882.09 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $314.48 | 2020-2022 | |
| Astellas Pharma US INC | $297.00 | 2020-2021 | |
| Philips North America LLC | $274.91 | 2022 | |
| Abiomed | $256.36 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $244.61 | 2019-2020 | |
| Spectrawave, INC | $234.39 | 2023 | Hypervue Imaging System |
| E.R. Squibb & Sons, L.L.C. | $218.67 | 2019-2025 | |
| Abbott Laboratories | $210.96 | 2021-2022 | |
| Medtronic, INC. | $208.48 | 2022-2025 | Kyphon Express II Kyphopak Tray |
| Terumo Medical Corporation | $144.03 | 2021 | |
| Angiodynamics, INC. | $137.97 | 2021 | |
| Novartis Pharmaceuticals Corporation | $98.22 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $67.01 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $66.82 | 2019 | |
| Esperion Therapeutics, INC. | $53.79 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.61 | 2019 | |
| Chiesi USA, INC. | $24.60 | 2020 | |
| Heartflow, INC. | $23.17 | 2023 | Ffrct |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pouya Mohajer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.